Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2025
0mins
Source: Benzinga
Coherent Corp Financial Results: Coherent Corp's shares surged 15.5% after reporting second-quarter earnings of 95 cents per share, exceeding analyst expectations of 69 cents, along with sales of $1.44 billion, surpassing the $1.37 billion estimate.
Pre-Market Stock Movements: Several stocks experienced significant pre-market trading fluctuations, with SharpLink Gaming gaining 43.5% and Avinger Inc dropping 29.4%, reflecting a mix of positive earnings reports and disappointing guidance across various companies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNA
Wall Street analysts forecast DNA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.030
Low
12.00
Averages
12.00
High
12.00
Current: 8.030
Low
12.00
Averages
12.00
High
12.00
About DNA
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks
- AI Strategy Partnership: ProQR Therapeutics announced the formation of an AI advisory board in collaboration with Ginkgo Bioworks, aiming to leverage artificial intelligence to enhance drug discovery efficiency on its RNA editing technology platform, Axiomer, which is expected to significantly accelerate the R&D process.
- Access to Technology Platform: Through the partnership with Ginkgo, ProQR will gain access to Ginkgo's Nebula, an autonomous lab with over 50 instruments, a move that will eliminate a key bottleneck in AI-enabled drug discovery, thereby enhancing overall R&D capabilities.
- Investment and Development: Ginkgo has made an undisclosed equity investment in ProQR, indicating confidence in ProQR's AI-driven drug discovery initiatives while providing financial support to expedite its R&D efforts.
- Clinical Data Expectations: ProQR plans to report initial clinical data from its inaugural AI-driven drug discovery program by the end of this year, with a clinical trial application expected in mid-2026, marking a significant advancement in its AI drug discovery efforts.
See More
PROQR FORMS AI ADVISORY BOARD AND PARTNERS WITH GINKGO BIOWORKS
Partnership Announcement: ProQR has announced a partnership with Ginkgo BioWorks to enhance its research and development efforts.
Formation of Advisory Board: The collaboration will also involve the formation of an advisory board to guide the partnership's initiatives.
See More
Elon Musk Could Rebuild Jurassic Park
- Musk's Wealth: Billionaire Elon Musk possesses enough wealth to buy every MLB, NBA, NFL, and NHL team, showcasing his immense influence in the global economy and potential for funding ambitious projects.
- Jurassic Park Franchise Success: Comcast's Jurassic Park franchise has grossed over $2.6 billion domestically, with the original 1993 film earning $357.1 million, highlighting its strong appeal in the entertainment industry.
- Biotech Advancements: Companies like Ginkgo Bioworks and Colossal Biosciences are working on de-extinction, with Ginkgo successfully reviving scents from extinct plants and Colossal bringing back the Dire Wolf in 2025, demonstrating the potential of modern biotechnology.
- Musk's Inspiration: Musk was inspired by X Head of Product Nikita Bier's post about Jurassic Park, expressing interest in reviving dinosaurs, although Colossal states there is currently no dinosaur DNA, reflecting the complex relationship between science and commercial aspirations.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Ginkgo Bioworks Stock Falls After Earnings Miss and Shift to Robotics Focus
- Earnings Miss: Ginkgo Bioworks' recent earnings report revealed a revenue miss, leading to a stock price decline that reflects market concerns about its future growth potential.
- Sales Decline: The reported sales figures fell short of analyst expectations, indicating that weak customer demand in the current market environment could hinder revenue growth.
- Strategic Shift: Ginkgo Bioworks is transitioning towards autonomous labs and robotics, aiming to enhance operational efficiency to tackle market challenges, although this shift may increase costs in the short term.
- Market Reaction: Investor response to the company's strategic shift has been cautious, as the stock price drop suggests a lack of confidence in the new strategy, which could impact future financing and investor relations.
See More
Ginkgo Bioworks Q4 Revenue Misses Expectations
- Revenue Decline: Ginkgo Bioworks reported Q4 revenue of $33 million, a 24.7% year-over-year decline that missed expectations by $4.57 million, indicating significant pressure in the competitive landscape.
- Cell Engineering Revenue Drop: The Q4 2025 cell engineering revenue was $26 million, down 26% from $35 million in the prior year, reflecting weakened customer demand and increasing market challenges.
- Biosecurity Revenue Decrease: Biosecurity revenue for Q4 was $7 million, down from $9 million in the same period last year, suggesting that growth potential in this area has not been realized, which may impact future investment decisions.
- Improved Net Loss: Although the GAAP net loss for Q4 was $81 million, an improvement from $108 million in the prior year, the adjusted EBITDA remained negative at $36 million, indicating ongoing efforts to control operating costs.
See More
ProQR Forms AI Advisory Board and Partners with Ginkgo Bioworks
- AI Strategy Partnership: ProQR Therapeutics announced the formation of an AI advisory board in collaboration with Ginkgo Bioworks, aiming to leverage artificial intelligence to enhance drug discovery efficiency on its RNA editing technology platform, Axiomer, which is expected to significantly accelerate the R&D process.
- Access to Technology Platform: Through the partnership with Ginkgo, ProQR will gain access to Ginkgo's Nebula, an autonomous lab with over 50 instruments, a move that will eliminate a key bottleneck in AI-enabled drug discovery, thereby enhancing overall R&D capabilities.
- Investment and Development: Ginkgo has made an undisclosed equity investment in ProQR, indicating confidence in ProQR's AI-driven drug discovery initiatives while providing financial support to expedite its R&D efforts.
- Clinical Data Expectations: ProQR plans to report initial clinical data from its inaugural AI-driven drug discovery program by the end of this year, with a clinical trial application expected in mid-2026, marking a significant advancement in its AI drug discovery efforts.
See More
PROQR FORMS AI ADVISORY BOARD AND PARTNERS WITH GINKGO BIOWORKS
Partnership Announcement: ProQR has announced a partnership with Ginkgo BioWorks to enhance its research and development efforts.
Formation of Advisory Board: The collaboration will also involve the formation of an advisory board to guide the partnership's initiatives.
See More
Elon Musk Could Rebuild Jurassic Park
- Musk's Wealth: Billionaire Elon Musk possesses enough wealth to buy every MLB, NBA, NFL, and NHL team, showcasing his immense influence in the global economy and potential for funding ambitious projects.
- Jurassic Park Franchise Success: Comcast's Jurassic Park franchise has grossed over $2.6 billion domestically, with the original 1993 film earning $357.1 million, highlighting its strong appeal in the entertainment industry.
- Biotech Advancements: Companies like Ginkgo Bioworks and Colossal Biosciences are working on de-extinction, with Ginkgo successfully reviving scents from extinct plants and Colossal bringing back the Dire Wolf in 2025, demonstrating the potential of modern biotechnology.
- Musk's Inspiration: Musk was inspired by X Head of Product Nikita Bier's post about Jurassic Park, expressing interest in reviving dinosaurs, although Colossal states there is currently no dinosaur DNA, reflecting the complex relationship between science and commercial aspirations.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Ginkgo Bioworks Stock Falls After Earnings Miss and Shift to Robotics Focus
- Earnings Miss: Ginkgo Bioworks' recent earnings report revealed a revenue miss, leading to a stock price decline that reflects market concerns about its future growth potential.
- Sales Decline: The reported sales figures fell short of analyst expectations, indicating that weak customer demand in the current market environment could hinder revenue growth.
- Strategic Shift: Ginkgo Bioworks is transitioning towards autonomous labs and robotics, aiming to enhance operational efficiency to tackle market challenges, although this shift may increase costs in the short term.
- Market Reaction: Investor response to the company's strategic shift has been cautious, as the stock price drop suggests a lack of confidence in the new strategy, which could impact future financing and investor relations.
See More
Ginkgo Bioworks Q4 Revenue Misses Expectations
- Revenue Decline: Ginkgo Bioworks reported Q4 revenue of $33 million, a 24.7% year-over-year decline that missed expectations by $4.57 million, indicating significant pressure in the competitive landscape.
- Cell Engineering Revenue Drop: The Q4 2025 cell engineering revenue was $26 million, down 26% from $35 million in the prior year, reflecting weakened customer demand and increasing market challenges.
- Biosecurity Revenue Decrease: Biosecurity revenue for Q4 was $7 million, down from $9 million in the same period last year, suggesting that growth potential in this area has not been realized, which may impact future investment decisions.
- Improved Net Loss: Although the GAAP net loss for Q4 was $81 million, an improvement from $108 million in the prior year, the adjusted EBITDA remained negative at $36 million, indicating ongoing efforts to control operating costs.
See More
